# Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

> **NCT07339059** · PHASE2 · RECRUITING · sponsor: **Bindu R Potugari** · enrollment: 35 (estimated)

## Conditions studied

- Small Cell Lung Cancer ( SCLC )
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)

## Interventions

- **DRUG:** Sacituzumab govitecan
- **DRUG:** Atezolizumab
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT07339059
- **Lead sponsor:** Bindu R Potugari
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2029-02-01
- **Final completion:** 2029-12-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07339059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07339059, "Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07339059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*